KR20230167755A - Parp7 억제제로서 유용한 트리시클릭 유도체 - Google Patents
Parp7 억제제로서 유용한 트리시클릭 유도체 Download PDFInfo
- Publication number
- KR20230167755A KR20230167755A KR1020237030816A KR20237030816A KR20230167755A KR 20230167755 A KR20230167755 A KR 20230167755A KR 1020237030816 A KR1020237030816 A KR 1020237030816A KR 20237030816 A KR20237030816 A KR 20237030816A KR 20230167755 A KR20230167755 A KR 20230167755A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- membered
- ring
- haloc
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/14—Oxygen atoms
- C07D237/16—Two oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/22—Nitrogen and oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2021076144 | 2021-02-09 | ||
| CNPCT/CN2021/076144 | 2021-02-09 | ||
| CNPCT/CN2021/091050 | 2021-04-29 | ||
| CN2021091050 | 2021-04-29 | ||
| CNPCT/CN2021/117189 | 2021-09-08 | ||
| CN2021117189 | 2021-09-08 | ||
| CN2021119368 | 2021-09-18 | ||
| CNPCT/CN2021/119368 | 2021-09-18 | ||
| CNPCT/CN2021/124714 | 2021-10-19 | ||
| CN2021124714 | 2021-10-19 | ||
| CN2021128807 | 2021-11-04 | ||
| CNPCT/CN2021/128807 | 2021-11-04 | ||
| CNPCT/CN2021/129056 | 2021-11-05 | ||
| CN2021129056 | 2021-11-05 | ||
| PCT/CN2022/073906 WO2022170974A1 (en) | 2021-02-09 | 2022-01-26 | Tricyclic derivatives useful as parp7 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230167755A true KR20230167755A (ko) | 2023-12-11 |
Family
ID=82838260
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020237030816A Pending KR20230167755A (ko) | 2021-02-09 | 2022-01-26 | Parp7 억제제로서 유용한 트리시클릭 유도체 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240336629A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4291560A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7885229B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR20230167755A (cg-RX-API-DMAC7.html) |
| CN (1) | CN116848114A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022220924A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112023015721A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3210885A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TW202246266A (cg-RX-API-DMAC7.html) |
| UY (1) | UY39625A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022170974A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240166664A1 (en) * | 2021-02-03 | 2024-05-23 | Shanghai Apeiron Therapeutics Company Limited | Triheterocyclic compound, preparation method therefor, and application thereof |
| WO2022223022A1 (zh) * | 2021-04-23 | 2022-10-27 | 四川海思科制药有限公司 | 一种并环杂环衍生物及其在医药上的应用 |
| WO2022247839A1 (zh) * | 2021-05-25 | 2022-12-01 | 山东轩竹医药科技有限公司 | Parp7抑制剂 |
| TW202416984A (zh) * | 2022-08-17 | 2024-05-01 | 大陸商北京加科思新藥研發有限公司 | 化合物i或其鹽的固體形式 |
| CN117551080A (zh) * | 2022-11-11 | 2024-02-13 | 杭州师范大学 | 一种靶向降解parp7的protac化合物及其制备方法与应用 |
| CN118388414A (zh) * | 2023-01-17 | 2024-07-26 | 中国药科大学 | 哒嗪酮类化合物及其制备方法、药物组合物和应用 |
| AU2024334795A1 (en) * | 2023-09-01 | 2026-04-02 | Chongqing Pharscin Innobio Co., Ltd. | Parp7 inhibitor and use thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103570725B (zh) * | 2012-08-01 | 2017-03-22 | 中国科学院上海药物研究所 | 哌嗪并三唑类化合物及其制备方法和用途 |
| CN103833756B (zh) * | 2012-11-26 | 2016-12-21 | 中国科学院上海药物研究所 | 一类哒嗪酮类化合物及其制备方法和用途 |
| US12435078B2 (en) | 2017-09-18 | 2025-10-07 | Gfb (Abc), Llc | Pyridazinones and methods of use thereof |
| BR112020022006A2 (pt) * | 2018-04-30 | 2021-01-26 | Ribon Therapeutics Inc. | piridazinonas como inibidores de parp7 |
| WO2020094084A1 (zh) * | 2018-11-07 | 2020-05-14 | 南京明德新药研发有限公司 | 作为ret抑制剂的三并环衍生物 |
| CN114096533B (zh) * | 2019-09-10 | 2024-03-08 | 四川科伦博泰生物医药股份有限公司 | 一种三并环类化合物,包含其的药物组合物,其制备方法及其用途 |
| WO2021087018A1 (en) * | 2019-10-30 | 2021-05-06 | Ribon Therapeutics, Inc. | Pyridazinones as parp7 inhibitors |
| TWI902715B (zh) | 2019-10-30 | 2025-11-01 | 美商律幫治療股份有限公司 | 作為parp7抑制劑的嗒酮 |
| US20240166664A1 (en) * | 2021-02-03 | 2024-05-23 | Shanghai Apeiron Therapeutics Company Limited | Triheterocyclic compound, preparation method therefor, and application thereof |
-
2022
- 2022-01-26 EP EP22752135.8A patent/EP4291560A4/en active Pending
- 2022-01-26 JP JP2023547775A patent/JP7885229B2/ja active Active
- 2022-01-26 WO PCT/CN2022/073906 patent/WO2022170974A1/en not_active Ceased
- 2022-01-26 CN CN202280014244.8A patent/CN116848114A/zh active Pending
- 2022-01-26 BR BR112023015721A patent/BR112023015721A2/pt not_active Application Discontinuation
- 2022-01-26 US US18/276,269 patent/US20240336629A1/en active Pending
- 2022-01-26 CA CA3210885A patent/CA3210885A1/en active Pending
- 2022-01-26 AU AU2022220924A patent/AU2022220924A1/en not_active Abandoned
- 2022-01-26 KR KR1020237030816A patent/KR20230167755A/ko active Pending
- 2022-01-26 TW TW111103378A patent/TW202246266A/zh unknown
- 2022-02-04 UY UY0001039625A patent/UY39625A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116848114A (zh) | 2023-10-03 |
| JP2024506612A (ja) | 2024-02-14 |
| AU2022220924A1 (en) | 2023-09-21 |
| EP4291560A1 (en) | 2023-12-20 |
| US20240336629A1 (en) | 2024-10-10 |
| BR112023015721A2 (pt) | 2023-11-07 |
| JP7885229B2 (ja) | 2026-07-06 |
| EP4291560A4 (en) | 2025-01-15 |
| WO2022170974A1 (en) | 2022-08-18 |
| WO2022170974A9 (en) | 2023-03-30 |
| CA3210885A1 (en) | 2022-08-18 |
| TW202246266A (zh) | 2022-12-01 |
| UY39625A (es) | 2022-09-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7644517B2 (ja) | Kras突然変異型タンパク質阻害剤 | |
| US20220370416A1 (en) | Compounds and methods for targeted degradation of kras | |
| JP6976953B2 (ja) | Rock阻害剤としてのスピロヘプタンサリチルアミドおよび関連性化合物 | |
| JP2024506612A (ja) | Parp7阻害剤として有用な三環式誘導体 | |
| US8614206B2 (en) | Pyrazol-4-yl-heterocyclyl-carboxamide compounds and methods of use | |
| AU2019228568B2 (en) | Piperidinyl-3-(aryloxy)propanamides and propanoates | |
| EA018988B1 (ru) | Активаторы глюкокиназы | |
| US20220363694A1 (en) | N-cyano-7-azanorbornane derivatives and uses thereof | |
| US20210292305A1 (en) | Cyclic Ureas | |
| CN113801111B (zh) | 联苯类衍生物抑制剂及其制备方法和应用 | |
| AU2012206527A1 (en) | BACE-2 inhibitors for the treatment of metabolic disorders | |
| US12060365B2 (en) | Cycloalkane-1,3-diamine derivative | |
| CN120025279A (zh) | 能够调节内质网氨肽酶1的化合物 | |
| US12319698B2 (en) | Proteasome activity enhancing compounds | |
| US20250195475A1 (en) | Cdk2 inhibitor and preparation method and use thereof | |
| JP2023526839A (ja) | アゼチジン環状尿素類 | |
| CN115151252A (zh) | 铁死亡抑制剂-二芳基胺对乙酰胺类 | |
| CN115697972B (zh) | 包括哌嗪杂环酰胺脲的受体-相互作用蛋白1抑制剂 | |
| US20230391774A1 (en) | Novel Compounds | |
| US11078186B2 (en) | ROR γ modulators | |
| US20230192659A1 (en) | N-(heterocyclyl and heterocyclylalkyl)-3-benzylpyridin-2-amine derivatives as sstr4 agonists | |
| US20240408169A1 (en) | Cyclin inhibitors | |
| US20240294508A1 (en) | Rip1 modulators including azetidine cyclic ureas, preparations, and uses thereof | |
| EP4722209A1 (en) | Protac compound targeting estrogen receptor, preparation method therefor, and use thereof | |
| US20250270209A1 (en) | Lrrk2 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20230908 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application |